Compare SUVEN LIFE with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUVEN LIFESCIENCES vs IPCA LABS - Comparison Results

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUVEN LIFESCIENCES IPCA LABS SUVEN LIFESCIENCES/
IPCA LABS
 
P/E (TTM) x 1.3 27.8 4.8% View Chart
P/BV x 0.3 5.6 5.5% View Chart
Dividend Yield % 7.4 0.2 3,426.8%  

Financials

 SUVEN LIFESCIENCES   IPCA LABS
EQUITY SHARE DATA
    SUVEN LIFESCIENCES
Mar-19
IPCA LABS
Mar-19
SUVEN LIFESCIENCES/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs3381,042 32.4%   
Low Rs169590 28.7%   
Sales per share (Unadj.) Rs52.1298.6 17.5%  
Earnings per share (Unadj.) Rs6.835.0 19.5%  
Cash flow per share (Unadj.) Rs8.649.4 17.3%  
Dividends per share (Unadj.) Rs1.503.00 50.0%  
Dividend yield (eoy) %0.60.4 160.9%  
Book value per share (Unadj.) Rs65.3247.1 26.4%  
Shares outstanding (eoy) m127.28126.35 100.7%   
Bonus/Rights/Conversions -ESOS-  
Price / Sales ratio x4.92.7 178.0%   
Avg P/E ratio x37.123.3 159.2%  
P/CF ratio (eoy) x29.616.5 179.2%  
Price / Book Value ratio x3.93.3 117.6%  
Dividend payout %22.08.6 256.2%   
Avg Mkt Cap Rs m32,272103,108 31.3%   
No. of employees `0001.113.4 8.0%   
Total wages/salary Rs m6617,874 8.4%   
Avg. sales/employee Rs Th6,132.22,807.0 218.5%   
Avg. wages/employee Rs Th611.1585.8 104.3%   
Avg. net profit/employee Rs Th803.5329.0 244.2%   
INCOME DATA
Net Sales Rs m6,63537,732 17.6%  
Other income Rs m242577 42.0%   
Total revenues Rs m6,87738,309 18.0%   
Gross profit Rs m1,6046,901 23.2%  
Depreciation Rs m2211,824 12.1%   
Interest Rs m38189 20.0%   
Profit before tax Rs m1,5875,465 29.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m7181,042 68.9%   
Profit after tax Rs m8694,422 19.7%  
Gross profit margin %24.218.3 132.2%  
Effective tax rate %45.219.1 237.1%   
Net profit margin %13.111.7 111.8%  
BALANCE SHEET DATA
Current assets Rs m6,23223,778 26.2%   
Current liabilities Rs m1,49010,975 13.6%   
Net working cap to sales %71.533.9 210.6%  
Current ratio x4.22.2 193.0%  
Inventory Days Days86104 83.3%  
Debtors Days Days8366 125.3%  
Net fixed assets Rs m4,04320,368 19.9%   
Share capital Rs m127253 50.4%   
"Free" reserves Rs m8,18330,971 26.4%   
Net worth Rs m8,31031,224 26.6%   
Long term debt Rs m181,409 1.3%   
Total assets Rs m10,38945,507 22.8%  
Interest coverage x43.130.0 143.9%   
Debt to equity ratio x00 4.7%  
Sales to assets ratio x0.60.8 77.0%   
Return on assets %8.710.1 86.2%  
Return on equity %10.514.2 73.9%  
Return on capital %19.517.3 112.6%  
Exports to sales %045.9 0.0%   
Imports to sales %016.6 0.0%   
Exports (fob) Rs mNA17,308 0.0%   
Imports (cif) Rs mNA6,266 0.0%   
Fx inflow Rs m5,62217,308 32.5%   
Fx outflow Rs m1,7996,266 28.7%   
Net fx Rs m3,82211,042 34.6%   
CASH FLOW
From Operations Rs m3564,923 7.2%  
From Investments Rs m-279-1,563 17.8%  
From Financial Activity Rs m-225-1,832 12.3%  
Net Cashflow Rs m-1481,528 -9.7%  

Share Holding

Indian Promoters % 63.4 45.9 138.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 11.4 -  
FIIs % 0.0 25.3 -  
ADR/GDR % 0.0 0.0 -  
Free float % 36.5 17.4 209.8%  
Shareholders   37,287 36,892 101.1%  
Pledged promoter(s) holding % 0.0 2.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUVEN LIFESCIENCES With:   ELDER PHARMA  FDC LTD.  SHASUN PHARMA  DISHMAN PHARMA  TTK HEALTHCARE  

Compare SUVEN LIFESCIENCES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Crashes 1,203 Points; IT and Banking Stocks Witness Selling(Closing)

Indian share markets extended losses in the first trading session of FY21, as the number of coronavirus cases in the country continued to rise.

Related Views on News

IPCA LABS Announces Quarterly Results (3QFY20); Net Profit Up 22.8% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 22.8% YoY). Sales on the other hand came in at Rs 11 bn (up 20.2% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (2QFY20); Net Profit Up 63.7% (Quarterly Result Update)

Nov 12, 2019 | Updated on Nov 12, 2019

For the quarter ended September 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 63.7% YoY). Sales on the other hand came in at Rs 12 bn (up 21.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

SUVEN LIFESCIENCES Announces Quarterly Results (1QFY20); Net Profit Up 47.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 572 m (up 47.2% YoY). Sales on the other hand came in at Rs 2 bn (up 3.8% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

IPCA LABS Announces Quarterly Results (1QFY20); Net Profit Up 101.5% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 101.5% YoY). Sales on the other hand came in at Rs 10 bn (up 18.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

SUVEN LIFESCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 22, 2019 | Updated on Jul 22, 2019

Here's an analysis of the annual report of SUVEN LIFESCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUVEN LIFESCIENCES. Also includes updates on the valuation of SUVEN LIFESCIENCES.

More Views on News

Most Popular

Sorry Warren Buffett, I'm Following This Man Instead of You in 2020(The 5 Minute Wrapup)

Mar 30, 2020

This man warned of an impending market correction while everyone else was celebrating the renewed optimism in early 2020...

A Big Trading Opportunity is Coming Your Way Soon(Fast Profits Daily)

Mar 25, 2020

I see a big opportunity to make fast profits on the horizon.

The Biggest Trading Opportunity of 2020 is Here...

Mar 26, 2020

India's #1 trader, Vijay Bhambwani, talks about a hugely profitable trading opportunity which you must know about today!

Coronavirus Sell-off Is a Perfect Time to 'Lockdown' this 'Crorepati' Stock(Profit Hunter)

Mar 24, 2020

Coronavirus crisis and panic selling has brought this quality smallcap to multiyear lows, making it a great bargain.

Lockdown! Now the Bailout...(The Honest Truth)

Mar 25, 2020

Ajit Dayal on what India should do to manage the coronavirus impact on the economy.

More

How to Trade the
Coronavirus Crash

Coronavirus Crash
Get this special report, authored by Equitymaster's top analysts, now.
We will never sell or rent your email id.
Please read our Terms

SUVEN LIFESCIENCES SHARE PRICE


Apr 1, 2020 (Close)

TRACK SUVEN LIFESCIENCES

  • Track your investment in SUVEN LIFESCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON SUVEN LIFESCIENCES

SUVEN LIFESCIENCES - CADILA HEALTHCARE COMPARISON

COMPARE SUVEN LIFESCIENCES WITH

MARKET STATS